Advances in the Management of Myeloma
Presented by Beth Faiman, PhD, MSN, APRN-BC, AOCN®, and Rachid Baz, MD
Cleveland Clinic, Cleveland, Ohio; and Moffitt Cancer Center, Tampa, Florida
Presenters’ disclosures of conflicts of interest are found at the end of this article.
J Adv Pract Oncol 2019;10(3):293–298 |
© 2019 Harborside™
New agents for the treatment of myeloma have individual and class effects that advanced practitioners need to know about when helping to keep their patients on treatment regimens. At JADPRO Live, Beth Faiman, PhD, MSN, APRN-BC, AOCN®, and Rachid Baz, MD, reviewed recent advances in induction regimens, treatment selection at relapse, and considerations when treating bone complications and amyloidosis.
For access to the full length article, please sign in